PeerVoice Oncology & Haematology Audio: Recent Episodes
PeerVoice
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours
Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML
Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice
Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals
Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts
Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED
Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer
Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting
Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence
Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes
Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events
Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer
Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML
Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer
Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem
Philippe Moreau, MD - Assessing Current and Potential Approaches in Multiple Myeloma: Updates From Madrid 2024
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy
Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients
David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey
María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance
Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma
Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer
Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy
Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer
Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?
Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes
George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action
Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line
Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey
Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct
Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations
Angela Lamarca, MD, PhD, MSc - Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplinary Care, Molecular Testing, and Targeted Treatment
Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not
Ken Herrmann, MD, MBA - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma
Aditya Bardia, MD, MPH - When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers
Karim Fizazi, MD, PhD - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment
Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma
David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC
Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma
Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC
Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?
Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice
Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
Nick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses
Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?
Emmanuella Guenova, MD, PhD - ‘T’ing Up Management of Mycosis Fungoides and Sézary Syndrome: Evaluating Blood Involvement and Its Impact on Patient Care
Jun-ichi Nishimura, MD, PhD / Austin Kulasekararaj, MD, FRCPath / Jeffrey Szer, MBBS, FRACP - Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: Applying Assessment and Mitigation Strategies for Patients Receiving Complement Inhibitors
Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?
Alicia K. Morgans, MD, MPH - What Would You Do Next? Exploring Expert Perspectives on Clinical Cases and Compelling Questions in mHSPC and nmCRPC
Thomas Powles, MBBS, MRCP, MD - Education, Collaboration and Communication: Aligning Patient and Clinical Priorities in Locally Advanced and Metastatic Urothelial Carcinoma
Mary Frances McMullin, MD, FRCP, FRCPath - Managing Myelofibrosis: Can We Do More to Address Cytopenias, Reduce Transfusion Burden, and Improve Quality of Life?
Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC
Silke Gillessen, MD - Optimal Treatment of mCRPC: What Is the Place of Radioligand Therapy?
Solange Peters, MD, PhD - Advancing Our Patient-Centered Approach to Care in ALK-Positive Metastatic Non-Small Cell Lung Cancer
Gerald Prager, MD - Don't Leave a Drug on the Table: Maximising Use and Benefits of Later-Line Treatments for Advanced Colorectal Cancer
Robert L. Coleman, MD - New Horizons in Cervical Cancer: Spotlight on Antibody-Drug Conjugates
Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing
Bruno Sangro, MD, PhD - A New Era in the Management of Advanced HCC: Sequencing Therapies for the Second-Line and Beyond
Susana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation
Isabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time
Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC
Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch
Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?
Mohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat
Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022
Rana R. McKay, MD - Practice Series on Translating Data Into Practice in mCRPC: The Evolving Role of Radiopharmaceuticals
Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias
Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC
Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022
Managing the Nuances of Paroxysmal Nocturnal Haemoglobinuria: Practical Strategies for Patients Receiving Complement Inhibitors
Immunotherapeutic Approaches in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Insights From the Real World
A Clinical Conversation on Metastatic Hormone-Sensitive Prostate Cancer: Intensifying Therapy Earlier in the Disease Course
Applying Revised Treatment Guidelines for Advanced Hepatocellular Carcinoma: Considerations in Real-Life Practice
The Place of Radiopharmaceuticals in an Evolving Treatment Landscape: Addressing Perceptions With Clinical Evidence to Optimise Outcomes in Men With Metastatic Prostate Cancer
Ensuring Long-Term Success in Advanced Ovarian Cancer: Sequencing Therapy Based on Science
Taking Check of Advanced Non-Melanoma Skin Cancers: Exploring the Clinical Impact of Systemic Immunotherapies
Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights from 2021 Virtual Congresses
Seeking a More Positive Outlook in Patients With mTNBC? Treatment Advances and How to Apply Them
The Need for Speed: Improving Diagnostic Accuracy and Effective Management of aTTP in Emergency and Intensive Care
An Immune System in Double Trouble: What Is ‘Best Practice’ for Managing Patients With Lymphoproliferative Malignancies?
Therapeutic Sequencing in Patients With Advanced or High Risk Hodgkin Lymphoma: Strategies in Action
Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses
Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?
Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?
Advanced Basal Cell Carcinoma: An Exploration of Clinical Challenges and What the Future Could Hold
Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer
Evolving Treatment Paradigm in Early-Stage EGFR-Mutant NSCLC: A Primer for Medical Oncologists
Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy
"Complementing Evidence With Expert Experience: Challenging Cases in Paroxysmal Nocturnal Haemoglobinuria "
Evolving the Treatment Paradigm in Metastatic HER2-Positive Breast Cancer: The Ongoing Story of Emerging Treatments
Beyond HPIs for Advanced Basal Cell Carcinoma: Exploring the Clinical Implications of New Evidence
Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management
Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data
Extending Overall Survival in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) While Maintaining Quality of Life: Can We Have it All?
Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease
Extending Your Interdisciplinary Understanding of IL-6R Inhibitors in Rheumatoid Arthritis
"Optimising the Use of JAK Inhibitors in RA: Translating the Latest Evidence Into Today’s Clinical Practice"
Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer
"Case Studies in Locally Advanced and Metastatic CSCC: Integrating Immunotherapy Into Current Treatment Paradigms"
Practical Lessons From Real-World Evidence on CDK 4/6 Inhibitors in Metastatic Breast Cancer
Changing Strategies for Changing Times: Optimising Use of Targeted Alpha Therapies for Advanced Prostate Cancer
Raising the Caliber of Non-Metastatic CRPC Care: Introducing Quality of Life Into the Equation
Evolving the Treatment Paradigm in HER2-Positive Breast Cancer: Are New Options on the Horizon?
The Evolving Landscape in Advanced CTCL: Can Emerging Therapies Enhance Patient Management?
Evolution of Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Approaches to Management
Immuno-oncology for mRCC: Considerations for a Combination Approach in the First-Line Setting
Warming Up to Novel Approaches for Primary Cold Agglutinin Disease: Strategies for Correct Diagnosis and Optimal Treatment
Maximising the Long-Term Treatment Plan for Unresectable Hepatocellular Carcinoma: A Sequential Approach to Improving Patient Outcomes
The Power of Personalised Medicine: CAR-T Immunotherapy for Treatment of Aggressive Large B-Cell Lymphoma
Optimising the Treatment of mRCC From the Start: Evaluating the Impact of Evolving First-Line Strategies
Aiming Higher in Advanced Cutaneous Squamous Cell Carcinoma: Experts Evaluate the Evidence for Immunotherapy
Emerging ‘Tumour-Agnostic’ Oncology Treatment: The Role of the Pathologist in Identifying Neurotrophic Tyrosine Kinase Gene Fusions
Merging Clinical Trial Results and Reality: The Real-World Implications of Androgen Receptor Antagonists for Non–Metastatic Castration-Resistant Prostate Cancer
Optimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression
Is There a Cardio-Oncologist in the House? Managing Risk for VTE and Stroke Due to AF in Patients With Cancer
Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Knowledge To Improve Outcomes
Best Practices for Use of Proteasome Inhibitors in the Treatment of Relapsed/Refractory Multiple Myeloma
Improving Treatment Monitoring and Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
Improving the Long-Term Treatment Plan for Patients With Metastatic Pancreatic Cancer: Insights From San Francisco
The Treatment Plan for Patients With Nonmetastatic Prostate Cancer in Canada: Optimizing the Journey From The Beginning
New Strategies, New Targets: The Evolving Landscape in Driver-Mutation–Positive Advanced NSCLC